ACE-031 1mg

For research use only — not for human or veterinary use.

Analytical Verification (COA)

Each batch of ACE-031 supplied by Grail Formula undergoes independent third-party laboratory verification to confirm compound identity, assay content, purity and microbiological safety.

Analytical testing for this batch was performed by Liquilabs s.r.o. (Czechia) using validated chromatographic and spectrometric techniques.

Batch: GF112025094

Key analytical results include:

• Assay Content: 0.966 mg
• Identification – Retention Time: 0.994
• Identification – Spectrum: 995
• Purity: greater than 99.8 percent
• Bacterial Endotoxins: below 0.001 EU per mg
• Total Aerobic Microbial Count: not detected
• Total Yeast and Mold Count: not detected

Independent heavy metal screening confirmed no detectable levels of arsenic, cadmium, cobalt, lead, nickel, mercury or vanadium.

These analytical procedures ensure traceability, purity verification and laboratory-grade compound consistency.

Product Overview

ACE-031 is a recombinant fusion protein research compound frequently studied in controlled laboratory environments focused on muscle growth regulation and signalling pathways associated with myostatin and activin receptors.

The compound belongs to a class of engineered biological molecules designed to interact with signalling pathways involved in skeletal muscle regulation and cellular growth processes.

This preparation contains 1 mg of high purity lyophilized compound supplied in a sealed research vial. The lyophilization process preserves structural stability and allows researchers to reconstitute the compound for controlled in vitro experimentation.

Because of its defined biological structure and stable analytical profile, ACE-031 has been referenced in experimental research models investigating muscle regulatory signalling systems.

Compound Overview

ACE-031 is a recombinant fusion protein derived from the extracellular domain of the activin receptor type IIB (ActRIIB) linked to a human immunoglobulin fragment.

This engineered structure allows the compound to interact with ligands involved in the myostatin and activin signalling pathways.

These pathways are associated with cellular processes that regulate muscle development, tissue growth and protein synthesis signalling networks.

Within experimental biochemical research, ACE-031 has been investigated for its interaction with regulatory growth factors involved in skeletal muscle signalling mechanisms.

Historical Background and Scientific Context

Scientific interest in muscle growth regulation increased significantly during the late twentieth century with the discovery of myostatin and its role in controlling skeletal muscle development.

During the early 2000s researchers began investigating receptor-based signalling pathways that regulate muscle tissue growth and cellular differentiation.

Activin receptor type IIB (ActRIIB) was identified as a key receptor involved in binding ligands such as myostatin and related growth factors.

As research into these pathways expanded, recombinant fusion proteins such as ACE-031 were developed to study ligand interactions and regulatory signalling mechanisms within controlled laboratory environments.

By the 2010s ACE-031 had become one of several compounds referenced in experimental research investigating muscle growth regulatory pathways and receptor signalling dynamics.

Mechanistic Focus in Research

Within experimental laboratory settings, ACE-031 is often studied in relation to activin receptor signalling and myostatin-related regulatory pathways.

Research investigations commonly explore the compound in experimental models examining:

• Activin receptor type IIB (ActRIIB) ligand interaction
• Myostatin signalling pathway modulation
• Skeletal muscle regulatory signalling systems
• Growth factor binding dynamics
• Cellular growth and differentiation pathways
• Comparative receptor-ligand interaction research
• Molecular signalling network modelling

These experimental models allow scientists to investigate biochemical regulatory mechanisms that influence cellular growth signalling and muscle regulatory pathways.

Research Applications

In controlled research environments, ACE-031 may be utilised in experimental models designed to explore signalling pathways associated with skeletal muscle regulation and receptor-ligand interactions.

Examples of research applications include:

• Myostatin pathway investigation
• Receptor-ligand interaction analysis
• Cell signalling research
• Molecular growth regulation studies
• Comparative protein interaction evaluation
• Intracellular signalling network modelling
• Controlled in vitro biological pathway studies

Grail Formula Quality

Every Grail Formula research compound is produced under strict quality control procedures designed to support reliable laboratory experimentation.

Each batch undergoes independent analytical testing to verify:

• Compound identity
• Assay accuracy
• Purity confirmation
• Microbial safety
• Endotoxin levels
• Heavy metal screening
• Full batch traceability

All testing is performed by independent laboratories to ensure transparent verification and reproducible research material.

Research Use Limitation

• Used solely for in vitro experiments
• Not permitted for clinical trials involving humans
• Not permitted for human or veterinary administration
• Not permitted for investigational human use

• Independently analysed by Liquilabs s.r.o. Czechia
• Greater than 99.8 % purity confirmed by COA
• Assay content verified at 0.966 mg
• Endotoxin level below 0.001 EU/mg
• No detectable heavy metals or microbial contamination
• Recombinant myostatin-pathway research compound
• For research use only – not for human or veterinary use

For laboratory research only. Not intended for human consumption, injection, or cosmetic use.

This product is for research purposes only. Not for human use or diagnostic/therapeutic applications. Keep out of reach of children.